Roivant jumps after Phase 3 NIU data show brepocitinib pushed median time-to-failure past 48 weeks
Market Chameleon (Wed, 21-Oct 10:47 AM)
Roivant (ROIV) sets Nov. 9 results call and Dec. 9 investor day, putting near-term focus on updates for LISRAYA, IMVT-1402, and mosliciguat
Market Chameleon (Wed, 21-Oct 7:44 AM)
